These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 12208224

  • 1. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy.
    Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, Heeschen C, Hamm CW, Robbins MA, Kleiman NS, Théroux P, White HD, Topol EJ.
    Eur Heart J; 2002 Sep; 23(18):1441-8. PubMed ID: 12208224
    [Abstract] [Full Text] [Related]

  • 2. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
    Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML.
    Lancet; 2002 Jan 19; 359(9302):189-98. PubMed ID: 11812552
    [Abstract] [Full Text] [Related]

  • 3. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Lauer MA, Houghtaling PL, Peterson JG, Granger CB, Bhatt DL, Sapp SK, Simoons ML, Harrington RA, Topol EJ, Lincoff AM, Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.
    Circulation; 2001 Dec 04; 104(23):2772-7. PubMed ID: 11733393
    [Abstract] [Full Text] [Related]

  • 4. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
    Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, Lansky AJ, Lincoff AM, Mehran R, Moses JW, Ohman M, White HD.
    Am Heart J; 2004 Nov 04; 148(5):764-75. PubMed ID: 15523305
    [Abstract] [Full Text] [Related]

  • 5. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
    Rajagopal V, Lincoff AM, Cohen DJ, Gurm HS, Hu T, Desmet WJ, Kleiman NS, Bittl JA, Feit F, Topol EJ.
    Am Heart J; 2006 Jul 04; 152(1):149-54. PubMed ID: 16824845
    [Abstract] [Full Text] [Related]

  • 6. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH, Harrington RA.
    Drugs; 1998 Dec 04; 56(6):965-76. PubMed ID: 9878986
    [Abstract] [Full Text] [Related]

  • 7. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA.
    Eur Heart J; 1998 Apr 04; 19 Suppl D():D10-21. PubMed ID: 9597518
    [Abstract] [Full Text] [Related]

  • 8. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
    Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD, ACUITY Investigators.
    JAMA; 2007 Feb 14; 297(6):591-602. PubMed ID: 17299194
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E, TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)--Thrombolysis in Myocardial Infarction 18 Investigators.
    N Engl J Med; 2001 Jun 21; 344(25):1879-87. PubMed ID: 11419424
    [Abstract] [Full Text] [Related]

  • 11. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
    Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators.
    Lancet; 2007 Mar 17; 369(9565):907-19. PubMed ID: 17368152
    [Abstract] [Full Text] [Related]

  • 12. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.
    Bosch X, Marrugat J.
    Cochrane Database Syst Rev; 2001 Mar 17; (4):CD002130. PubMed ID: 11687143
    [Abstract] [Full Text] [Related]

  • 13. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.
    Vorchheimer DA, Badimon JJ, Fuster V.
    JAMA; 1999 Apr 21; 281(15):1407-14. PubMed ID: 10217057
    [Abstract] [Full Text] [Related]

  • 14. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Mänttäri M, White HD, Califf RM, Topol EJ.
    Am Heart J; 2002 Dec 21; 144(6):995-1002. PubMed ID: 12486423
    [Abstract] [Full Text] [Related]

  • 15. Benefit of an early invasive management strategy in women with acute coronary syndromes.
    Glaser R, Herrmann HC, Murphy SA, Demopoulos LA, DiBattiste PM, Cannon CP, Braunwald E.
    JAMA; 2002 Dec 25; 288(24):3124-9. PubMed ID: 12495392
    [Abstract] [Full Text] [Related]

  • 16. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G, Neumann FJ, Deliargyris EN, Mehran R, Mehilli J, Ferenc M, Schulz S, Schömig A, Kastrati A, Stone GW.
    Circ Cardiovasc Interv; 2012 Oct 25; 5(5):705-12. PubMed ID: 23048052
    [Abstract] [Full Text] [Related]

  • 17. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
    Akkerhuis KM, Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, Baardman T, Nehmiz G, Roth U, Klootwijk AP, Deckers JW, Simoons ML, Fibrinogen Receptor Occupancy Study (FROST) Investigators.
    Eur Heart J; 2000 Dec 25; 21(24):2042-55. PubMed ID: 11102255
    [Abstract] [Full Text] [Related]

  • 18. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R, Sardar P, Amin H, Swaminathan RV, Kim LK, Chatterjee S, Feldman DN.
    Am J Cardiol; 2014 Jul 15; 114(2):250-9. PubMed ID: 24890986
    [Abstract] [Full Text] [Related]

  • 19. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.
    Circulation; 1998 Jun 23; 97(24):2386-95. PubMed ID: 9641689
    [Abstract] [Full Text] [Related]

  • 20. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
    Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators.
    JAMA; 2004 Aug 11; 292(6):696-703. PubMed ID: 15304466
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.